Assessment of aprotinin influence on periodontal clinical status and matrix metalloproteinases 1, 2 and their tissue inhibitors saliva concentrations in patients with chronic periodontitis
| Autor: | Janusz Zak, Beata Zelazowska, Anna Bernaczyk, Jolanta Wysocka, Jan Pietruski, A Paniczko-Drezek, Małgorzata Pietruska, Anna Skurska, Ewa Dolińska |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male Periodontium medicine.medical_specialty Saliva Serine Proteinase Inhibitors Gingival and periodontal pocket Bleeding on probing Dentistry Gastroenterology Root Planing Aprotinin Internal medicine Periodontal Attachment Loss Medicine Humans Periodontal Pocket Aged Periodontitis Tissue Inhibitor of Metalloproteinase-2 Tissue Inhibitor of Metalloproteinase-1 business.industry Therapeutic effect Dental Plaque Index General Medicine Middle Aged medicine.disease Chronic periodontitis Clinical attachment loss Chronic Periodontitis Dental Scaling Matrix Metalloproteinase 2 Female medicine.symptom Matrix Metalloproteinase 1 Periodontal Index business Gingival Hemorrhage medicine.drug |
| Zdroj: | Advances in medical sciences. 54(2) |
| ISSN: | 1898-4002 |
| Popis: | Purpose: Assessment of the effect of treatment with aprotinin-containing drug on the clinical status of the periodontal tissue and on the concentrations of metalloproteinases released in the course of periodontitis (MMP-1, MMP-2) as well as their tissue inhibitors (TIMP-1 and TIMP-2) in the saliva of patients with chronic periodontitis (CP). Material/Methods: The study involved 25 subjects with CP (39-68 years), including 16 women and 9 men. The patients were prescribed aprotinin preparation to be taken for 2 weeks. The control group (C) involved 14 healthy subjects (41-65 years), including 10 women and 4 men. Two periodontal indices were assessed: the approximal plaque index (API) and bleeding on probing index (BOP). Periodontal pocket depth and clinical attachment level were also evaluated. The concentrations of MMP-1 and MMP-2 as well as TIMP-1 and TIMP-2 were determined by the ELISA method. Results: The mean salivary MMP-1 concentration in patients with CP was significantly higher before and after treatment, as compared to healthy subjects. The mean salivary MMP-2 concentration in CP patients at baseline was also higher as compared to the C group and increased after treatment. The mean salivary TIMP-1 and TIMP-2 concentration in CP patients was higher as compared to C group and increased after treatment. Conclusions: Since the mean MMPs levels were found to be growing it can be assumed that aprotinin has no significant effect on the regulation of MMPs in the saliva of CP patients. It thus seems that aprotinin application after scaling has no additional therapeutic effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|